AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02049788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Description: Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
Study NCT01352910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 120 pulses 0.2 Hz
Study NCT01352910 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: 120 pulses 0.2 Hz
Study NCT02517567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Description: Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
Study NCT02517567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
Study NCT02517567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
Study NCT01699906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet regimen to induce weight loss
Description: Diet regimen to induce weight loss
Study NCT05108155 — intervention group
Intervention type: PROCEDURE
Intervention: Cemented THA
Description: THA with cement fixation
Study NCT05108155 — intervention group
Intervention type: PROCEDURE
Intervention: Unemented THA
Description: THA with uncemented / pressfit fixation
Study NCT05384093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Stretch Device
Description: High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
Study NCT00006237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interleukin-2
Description: Given IV
Study NCT04445051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath® Standard male or female
Description: Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male or female.
Study NCT04445051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 1 catheter for male or female
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 for male or female.
Study NCT04445051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 2 catheter for male or female
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 for male or female.
Study NCT01506219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Geriatrician-performed CGC
Description: Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
Study NCT00479349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAM-531
Description: Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
Study NCT01949857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated HAV Vaccine, H2 Strain
Description: 6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
Study NCT01949857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated HAV Vaccine, L-A-1 Strain
Description: 6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
Study NCT01949857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated HAV Vaccine, Lu8 Strain
Description: 320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
Study NCT01949857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated HAV Vaccine, TZ84 Strain
Description: 250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.
Study NCT04134728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
Study NCT04134728 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
Study NCT04134728 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab
Description: Sarilumab solution in PFS to be administered SC.
Study NCT04134728 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sarilumab
Description: Sarilumab solution in PFS to be administered SC.
Study NCT04134728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to GSK3196165/ Sarilumab
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
Study NCT04134728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to GSK3196165/ Sarilumab
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
Study NCT04134728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.
Study NCT04134728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.
Study NCT04134728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: csDMARDs
Description: Stable dose of csDMARD(s) as SoC.
Study NCT03905824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic stromal mesenchymal cells derived from the umbilical cord
Description: Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
Study NCT03905824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement and microfracture
Description: Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
Study NCT03905824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement and microfracture
Description: Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
Study NCT00794755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1 (Phytonadione)
Description: Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
Study NCT00794755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
Study NCT03945201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual walking trails
Description: During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.
Study NCT03945201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes.
Study NCT02478918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call
Description: Automated phone call reminder
Study NCT04479449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203
Description: SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
Study NCT02001831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Study NCT02001831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00006237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00006237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: interferon alfa
Description: Given IV and subcutaneously
Study NCT00006237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interferon alfa
Description: Given IV and subcutaneously
Study NCT00006237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00006237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Given IV
Study NCT00006237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Given IV
Study NCT02200562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab and dabrafenib
Study NCT03409835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron 0.3 mg is administered after induction of general anesthesia.
Study NCT03409835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2 ml is administered after induction of general anesthesia.
Study NCT03641443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of intracranial pressure
Description: Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
Study NCT06242158 — intervention group
Intervention type: PROCEDURE
Intervention: arthroscopic assisted mini-open 5 step repair
Description: First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair
Study NCT03335098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Six 4-week cycles
Study NCT01910025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study NCT02216591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cognitive Training (ACT)
Study NCT02216591 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control (CON)
Study NCT02615730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
Study NCT02615730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
Study NCT03366155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Codman 3000 constant flow pump catheter
Description: implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
Study NCT03366155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg, IV
Study NCT03366155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUDR-Dex
Description: HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
Study NCT03366155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, IV
Study NCT03366155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
Study NCT03366155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2, IV
Study NCT03366155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIP installation
Description: HAI pump installation
Study NCT04479449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study NCT03619837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir
Description: Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
Study NCT03619837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir
Description: Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks.
Study NCT00533169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
Study NCT00533169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic Acid
Description: Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV Q3W
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI305
Description: 15mg/kg IV Q3W
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500mg/m2 IV Q3W
Study NCT04575766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-7051
Description: Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level.
Study NCT00527306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
Study NCT00527306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
Study NCT00106067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping and communication support (CCS) intervention
Description: Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families.
Study NCT03760003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 25mg
Description: ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
Study NCT03760003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 50mg
Description: ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
Study NCT03760003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 100mg
Description: ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
Study NCT03760003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of placebo once daily for 16 weeks
Study NCT00638027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched tablets bid
Study NCT00638027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: 10 mg bid
Study NCT05227911 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal Surgery
Description: Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
Study NCT02519738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
Study NCT02519738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog (Triamcinolone)
Description: Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
Study NCT02519738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Washcloth Abrasion
Description: Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
Study NCT00144911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Study NCT00144911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Combination Product
Study NCT02303041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Administered orally at starting dose of 80 mg/day
Study NCT02303041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Administered orally at starting dose of 200 mg/day
Study NCT00553306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV
Study NCT00553306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously
Study NCT00553306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00553306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT00553306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Optional correlative studies
Study NCT00553306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00553306 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT02032095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-0998
Study NCT03441932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Description: Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree.
Study NCT00671918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Description: Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.